Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment

被引：0
|
作者：
Hou, Jing-Zhou
Li, John
Vasudevan, Anupama
Gart, Mike
Choksi, Rushir J.
Blanc, Simon
机构：
[1] Univ Pittsburgh Med Ctr UPMC, Pittsburgh, PA USA
[2] Integra Connect PrecisionQ, W Palm Beach, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19027
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT)
    Ran, Tao
    He, Jinghua
    Wu, Linda
    Panjabi, Sumeet
    Lu, Xiaoxiao
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S275 - S276
  • [32] First-Line Treatment Outcomes of CML Patients in a Real-World Data Setting in Lebanon
    Nasr, Fadi
    Yehia, Intissar
    El Khoury, Reem
    Diab, Saada
    Al Ghoche, Ahmad
    Nasr, Lewis
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S332 - S333
  • [33] First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
    Wang, M.
    Dhokia, P.
    Menon, S.
    Martindale, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 22 - 22
  • [34] Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients
    Sun, Gordon H.
    Neary, Maureen P.
    Chang, Eunice
    Broder, Michael S.
    PANCREAS, 2015, 44 (02) : 359 - 360
  • [35] Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.
    Dennen, Syvart
    Boppudi Naga, Sai Sriteja
    Cockrum, Paul
    Paluri, Ravi Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 629 - 629
  • [36] Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
    Narezkina, Anna
    Akhter, Nausheen
    Lu, Xiaoxiao
    Emond, Bruno
    Huang, Qing
    Panjabi, Sumeet
    Hilts, Annalise
    Lu, Stephanie
    Lafeuille, Helene
    Lafeuille, Marie-Helene
    Choi, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S276 - S277
  • [37] Chronic Lymphocytic Leukemia (CLL) Advances in the Treatment of High-risk Patients
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (12) : 842 - 842
  • [38] Overall and Subgroup Results from the Third Interim Analysis of FIRE, a Real-World Study of Ibrutinib Treatment for CLL/SLL in France
    Dartigeas, Caroline
    Ysebaert, Loic
    Feugier, Pierre
    Delmer, Alain
    Dupuis, Sandrine
    Deslandes, Marine
    Lahaye, Marjolein
    Leblond, Veronique
    BLOOD, 2022, 140 : 9906 - 9907
  • [39] Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi
    Moslehi, Javid J.
    Wahlstrom, Svea K.
    Teschemaker, Anna
    Mackey, Rachel H.
    DeVincenzo, Diana
    Carabuena, Leslie A.
    Thompson, Samantha L.
    Gordon, Brittaney
    Rosenthal, Ning A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison
    Mahn, Robert
    Glueer, Oscar Andre
    Sadeghlar, Farsaneh
    Moehring, Christian
    Zhou, Taotao
    Anhalt, Thomas
    Monin, Malte Benedikt
    Kania, Alexander
    Glowka, Tim R.
    Feldmann, Georg
    Brossart, Peter
    Kalff, Joerg C.
    Schmidt-Wolf, Ingo G. H.
    Strassburg, Christian P.
    Gonzalez-Carmona, Maria A.
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 81 - 94
12345